CytoDyn Inc (QB) (CYDY) News

He doesn’t have to explain anything to you, it’s his opinion, just like we all have, it’s completely legal in the states, thank you for playing

Explain why it would be coming soon. Hmm? They haven't started recruiting for the only study even close to happening. So please explain why it would be coming soon. I'm all ears (you won't explain because you can't it's pure hopium you're basing that on)

Thank you a great deal doc!! You're extremely informative let alone extremely intellectual. I really appreciate and enjoy reading your post. Especially your latest lengthy one. Yes we are going up and up and away We go. Just a matter of time and that's in my opinion coming quite soon. My opinion of course. Thank you again a great deal Nik1

He's a phizer phan loving those dividends on a long tanking stock. Of course, I wonder what else he/she/it would recommend?
FDA is cracking down on the instability of these mRNA junk jabs. New sheriff in town is focused on making America healthier again.
Who would not be for that? We know who, and we know that those days are rapidly coming to an end.

Yes, shorts pile on. I need some more cheapies before the surge.

Look for a PR coming to validate that premature posting. No? Watch.

Well, I took my information from this company's website, but what do they know?

docj- great post and comparison.
Chump

Thats actually not true. Drugs that improve survival or quality of life in oncology are typically approved in under three years. A recent article came out about this.

Tiny-Ad-8280

“It’s Just a Poster…” Until It Saves Lives. 40 Days...
Let’s not sugarcoat it.

“It’s just a poster.” “We’ve been here before.” “If this were real, we’d already know.”

That’s what they’re saying.
Some with cynicism.
Some with scars.
And honestly? I get it.

But if you’ve ever paid attention to oncology, you know:

The biggest revolutions start small.

And this one — if it holds — could be one of the biggest of all.

🧬 Let’s rewind to 2015
Immunomedics walked into ASCO with Trodelvy, a drug nobody cared about yet.

58 women with stage 4 triple-negative breast cancer

17 had some tumor shrinkage

2 had full tumor disappearance

No survival data

No media frenzy

Just a quiet little poster tacked to a wall

No one said,

“This changes everything.”

But five years later?
Trodelvy becomes the largest breast cancer acquisition in history.
$21 billion.
Because that poster was the spark.

It didn’t show a cure.
It showed a signal.

🧬 Now it’s 2025. And Leronlimab is bringing more than a signal.
It’s not just a tumor response.
It’s not a 3-month bump in survival.

It’s stage 4 breast cancer patients — alive and well, three years later.
It’s people who failed every line of chemo — now cancer-free.
It’s data that, if true, doesn’t just whisper “potential.”

It screams: hope is back.

Let me make this brutally clear:

✅ This is metastatic triple-negative breast cancer
✅ The kind that kills in 6–12 months, even with treatment
✅ These women were told, “There’s nothing more we can do.”
✅ And now some are alive 36+ months later, with no cancer left to find

You don’t see that.
Not in this disease.
Not at this stage.
Not ever.

📊 Let’s stack it side by side — facts only:
🧬 Trodelvy (2015) vs Leronlimab (2025)
Poster vs Poster. Hope vs Survival.

Metric Trodelvy (2015 Poster at ASCO) Leronlimab (2025 Poster at ESMO)
Trial Phase Phase 1/2 Phase 1b/2 (Basket Trial)
Patients 58 with mTNBC (chemo-refractory) 30 with mTNBC (chemo-refractory)
Tumor Shrinkage 17 of 58 (~31% response rate) Some complete responses (NED); numbers coming at ESMO
Complete Remissions 2 confirmed Confirmed NED cases; final count revealed at ESMO
Median Survival Not reported >50% alive at 12 months
Long-Term Survivors None reported 36+ monthsSome alive , cancer-free
Grade 3/4 Side Effects 39% neutropenia, 13% diarrhea (chemo-like toxicity) Zero Grade 3/4 treatment-related adverse events
Now let me decode that last line for everyone without a medical degree:

🩸 Trodelvy’s early success came with real toxicity.

4 in 10 patients developed neutropenia — dangerously low white blood cells that can lead to life-threatening infections.

Over 1 in 10 had severe diarrhea — the kind that can land you in the hospital.

These are Grade 3 or 4 side effects, the most serious in cancer trials. They’re manageable — but not easy. This is classic, brutal chemo.

🌱 Leronlimab’s early trial?
Zero of those severe, drug-related side effects reported.
Not one patient experienced life-altering toxicity due to the drug.
No fevers. No bone marrow suppression. No emergency transfusions.
Just a targeted immune modulator that — somehow — gave patients time, without taking their quality of life.

You know what that means?
These women weren’t just alive longer.

They were living longer — without suffering.

That is not normal. That is not expected. That is not pharma-as-usual.

That is a breakthrough.

“But it’s just a poster…”
Yes.
So was Trodelvy.

So were the first data points from Keytruda, from Opdivo, from every life-saving drug in oncology history.

Because posters are where revolutions begin.

And this one?
Might be the most important ever tacked to a conference wall.

TL;DR:
“We’ve seen this before.”

No. You haven’t.

You’ve seen companies chase survival.
Now you’re seeing it.

You’ve seen drugs buy patients time.
Now you’re seeing people beat the clock.

And in 40 days, on a poster board in Munich,
you’ll see the data that proves it.

So roll your eyes.
Call it hype.
Say “we’ve heard this before.”

But when those survival curves drop…
when you see “36+ months” in a disease that gives you 6…

You’ll remember this post.

And you’ll realize:

This wasn’t another story.
This was the beginning of the ending — of metastatic breast cancer.

— Tiny 🧬

Longs I don’t want to give shorts ammunition I had my fun.

Hold tight almost there. Let them guess and try to time the market. They are going to fail.

why do you care what others buy. if you feel you want to buy other stocks ,do it.

So then, as many have pointed out.....the COMPANY is stating they are years and years away from possibly having a drug approved.
Remind me why you'd be buying this now vs years from now? Getting in early might mean 6 years from now. It sure won't be before a drug gets to phase III or actually approved. Anyone else consider there are other pharma companies that also work on getting new drugs approved?

What's the value of time?

All you are seeing in this stock now is pumping and dumping. Posters will come and go.

This company gets so little done the pumpers have resorted to cheering on a website redesign. How pathetic is that
A botched website redesign!

Even that cannot be done properly.

They are being paid to burn cash in the most inefficient way possible.

Funded with bagholders’ capital.

This company gets so little done the pumpers have resorted to cheering on a website redesign. How pathetic is that

After everything we have been through as shareholders, and now a screw up on updated website labeling a phase 3 trail instead of phase 2, absolutely can’t make it up, how stupid. Kill me, shorts enjoy🤪😵‍💫

Website corrected regarding CRC:

https://www.cytodyn.com/pipeline

Fake message

The posted message did not say that, as ihub records prove

And you know that.

Please do not post fake messages.

Tiny-Ad-8280

🧬 A Tiny Dose of CYDY — 41 Days to ESMO
“Phase 3? Wait… what?”

You’re not crazy. CytoDyn just updated their website to show the CRC (colorectal cancer) trial as Phase 3 — even though ClinicalTrials.gov still says Phase 2.

So what gives?

Let’s break it down for everyone wondering the same thing 👇

🧪 First: Can you skip from Phase 2 to Phase 3?
Yes — but not without serious work behind the scenes.

To call something a Phase 3 trial, CytoDyn would’ve had to:

Amend the protocol (trial plan) to reflect Phase 3 endpoints — meaning stricter goals, more patients, usually randomized.

Submit that new plan to the FDA under their IND (Investigational New Drug) application.

Wait for FDA sign-off — if the FDA doesn’t issue a “clinical hold,” the trial can proceed as Phase 3.

This isn’t a blog edit. It’s regulatory law.

🧠 Why would the website show Phase 3 if ClinicalTrials.gov doesn’t?
A few totally legit reasons:

ClinicalTrials.gov updates slowly. It often takes weeks after a trial is amended or begins dosing before the public registry is updated.

They’re waiting for “First Patient In” (FPI) — which is when most companies announce a trial has officially begun.

They may be saving the announcement for ESMO — when everyone’s watching.

This kind of update doesn’t happen by accident. You don’t “misclick” a Phase 3.

📰 But shouldn’t they PR it?
Short answer: they will.

Companies typically issue press releases when:

The first patient is treated in the new trial.

They want to make a big splash — like pairing the CRC Phase 3 with mTNBC survival data at ESMO.

Or when it’s strategically beneficial (e.g. upcoming financing, partnership talks, etc.).

Until then? They’re allowed to update internal and investor materials — especially if they’re accurate.

🎯 So is this real?
🧠 Logically? Yes.

They wouldn’t update a website during a critical moment — with all eyes on them — unless this was intentional and grounded in upcoming action.

And the fact that this trial is being run with Syneos and Georgetown’s Dr. Ben Weinberg as PI (Principal Investigator)? That’s serious firepower. You don’t upgrade to Phase 3 unless the foundation is there.

📈 So what does this mean for the stock?
Let’s be real here:

41 days to ESMO with mTNBC survival data showing 36+ months NED in stage 4 cancer

A website quietly updated to show a Phase 3 CRC trial

Short interest rising (now at 28 million shares)

And a share price still in the 20-cent range

That’s a setup. A real one.

If ESMO hits like we think it will — and the CRC trial is truly Phase 3 — the price action won’t be subtle.

This is the calm before the chart.

TL;DR:
This Phase 3 listing is probably legit.
The market hasn’t noticed.
But the ones shorting this?
They’re about to.

41 days.
And counting.

— Tiny 🧬

Wow, of course. I would venture to say it is because of a license or partnership that is in excellent standing with the FDA and new drug administrators within the FDA that are proactive based on real data. The turnaround here is amazing. This will attract some smart investors and research scientist will do a double take.

Watch the real paid pigs start to squeal. That's the buy signal.

$$$NBRI$$$ Big revelations coming!!

I was wondering about that even before it happened. Why not?

Designer_Anteater_18

Reasons to go from Phase 2 to Phase 3 colorectal trial before enrollment
How did cytodyn move its colorectal trial from a phase 2 trial to a phase 3 trial? What could have happened to have this change before enrollment?

ChatGPT said:
If CytoDyn has moved its relapsed/refractory microsatellite-stable colorectal cancer (CRC) trial from Phase 2 to Phase 3 before enrollment, several key factors could have influenced this shift:

Possible Reasons for the Change:
Strong Preliminary Data

If CytoDyn or its research partners (Syneos Health, academic institutions, or other collaborators) provided compelling preclinical or early clinical data (such as compassionate use or investigator-led studies), the FDA might have been convinced that a Phase 3 trial was justified.

Fast Track or Breakthrough Designation

If the FDA granted Fast Track, Breakthrough Therapy, or Accelerated Approval pathways, they may have allowed the trial to jump directly to Phase 3 to expedite approval.

Agreement with the FDA (End-of-Phase 2 Meeting)

CytoDyn may have had discussions with the FDA in an End-of-Phase 2 meeting, where they provided data that satisfied Phase 2 requirements and allowed for a direct transition to Phase 3.

Regulatory Strategy Change

CytoDyn might have restructured its clinical trial design (e.g., increasing sample size, modifying endpoints) to meet Phase 3 standards upfront, possibly in alignment with a potential partner’s requirements.

A Confirmatory Trial Approach

If the FDA agreed that Phase 2 endpoints were sufficient for efficacy, CytoDyn could have adjusted the trial into a pivotal Phase 3 study serving as a confirmatory trial for approval.

Potential Partnership Influence

A pharmaceutical partner (GSK, Merck, or another company) might have pushed for a direct Phase 3 trial as part of a licensing deal.

Updated Scientific Findings (CCR5 Mechanism in Oncology)

New discoveries or peer-reviewed studies supporting CCR5 inhibition in colorectal cancer might have strengthened the case for a direct Phase 3 move.

What Would This Mean for CytoDyn?
Saves time: Skipping Phase 2 saves 1-2 years in the regulatory process.

Higher valuation: A Phase 3 asset attracts more partnerships, institutional investors, and buyout interest.

Increased funding opportunities: Moving to Phase 3 suggests FDA confidence, which can help raise money from investors or government grants.

This move could be huge for CytoDyn, especially if it means leronlimab’s oncology applications are proving to be strong enough to go straight to a pivotal trial.

The Cytodyn pig is even uglier now

At least the lipstick was pretty in the previous version LOL

More shareholder capital thrown out of the window

Instead of … like … real biotech work …ya know… some real control arm to compare Lemonlimab against…the very thing that is always carefully avoided by management LOL

Website new look/rebranding underway:

https://www.cytodyn.com/


CRC listed as Phase 3????

CytoDyn looks to get a fair shot finally ... https://news.spreely.com/rfk-jr-plans-to-eliminate-vaccine-promotion-and-hiv-prevention-offices-by-jordan-conradson/

Health and Human Services Secretary Robert F. Kennedy Jr. is making headlines with his ambitious plan to overhaul the sprawling department. As part of his bold initiative to streamline operations and cut down on government bloat, Kennedy has set in motion a plan to reduce the HHS workforce by 20,000 employees. This transformative move underscores his commitment to shrinking the size of the federal government — a principle championed by conservative icons like Ronald Reagan.

One of the most significant steps Kennedy has taken is targeting the Office of Infectious Disease and HIV/AIDS Policy (OIDP) for restructuring. This office, which has been at the forefront of promoting expansive vaccination campaigns, is set to face massive layoffs. Kennedy’s decisive action sends a clear message: under his leadership, HHS will focus on efficient, transparent, and accountable public health practices rather than perpetuating bloated bureaucratic structures.

Critics of OIDP have long argued that the office became too focused on promoting vaccine mandates without sufficiently addressing safety concerns or acknowledging adverse reactions. By downsizing OIDP, Kennedy is signaling his intent to move away from coercive health policies and toward a more balanced, evidence-based approach.

Kennedy’s efforts are a direct challenge to the controversial legacy left by Dr. Anthony Fauci at the National Institute of Allergy and Infectious Diseases (NIAID). Fauci’s tenure has been marked by widespread criticism over his handling of both the COVID-19 pandemic and the AIDS crisis. Under Fauci’s leadership, public confidence in health agencies plummeted as contradictory guidance and rushed vaccine approvals left Americans feeling uncertain and betrayed.

Particularly concerning is the fallout from the COVID-19 vaccine rollout. Critics point to thousands of deaths and severe adverse reactions linked to the vaccine, raising serious questions about the FDA’s approval process. Kennedy, who has long advocated for vaccine safety and transparency, is determined to hold public health officials accountable for pushing experimental vaccines without sufficient long-term studies.

That's been covered moron. Get up to snuff.

Pretty hilarious they said they would start recruiting in January and it's now April and still no recruiting. Anyone not a moron would see the writing on the wall

The only person dumping is you.

So I should probably tell Dr Chan that he’s being scammed, right, or Dr. Campbell that helped him get on Leronlimab, is that just all lies and fraud you say, nine months later and he still living, without it spreading, I say you are the fraud here, oh, and I know him by way FF

You look so immature and insecure with such sentence. Black Ops had the same tell.

CYDY is a badly led scam and you are just making the pump & dump pig look worse than it looks already.

https://www.allpennystocks.com/specialreportsus/3828/micro-cap-surging-on-company-developed-ccr5-antagonist-showing-promise-in-patients

Dr. Jacob Lalezari, CEO of CytoDyn, added: “These provocative observations of improved survival in patients with mTNBC and prior treatment failure in the metastatic setting, including reported clearance of disease in a group of long-term survivors, provides early clinical evidence of leronlimab’s potential impact in the treatment of TNBC and other solid tumors. I expect the Company’s oncology efforts to accelerate in the coming months, with further announcements in both mTNBC and colorectal cancer.”

Blessed weekend for all.

$$$CYDY$$$ 2025

About Merck’s research in women’s cancers

Merck is advancing research aimed at expanding treatment options for certain breast and gynecologic (ovarian, cervical and endometrial) cancers, with a goal of improving outcomes for more patients affected by these diseases. Breast cancer and gynecological cancers are the first and second most commonly occurring cancer types among women worldwide, respectively, and Merck aims to give patients facing these devastating diseases options. With more than 20 clinical trials in more than 18,000 patients around the world, Merck is driving innovative research to purposefully advance standards of care in women’s cancers. Merck’s research efforts include trials focused on evaluating its medicines in earlier stages, as well as identifying novel mechanisms and new combinations with these treatments. Merck is working to develop a portfolio and pipeline to address the impact of women’s cancers on patients, their families and communities globally.

Keytruda failed colon cancer but passed for what??? Who would approve this turda? That is the key question.

Discontinuation of KEYTRUDA due to adverse reactions occurred in 21% of 488 patients; the most common (≥1%) were increased ALT (1.6%), colitis (1%), and adrenal insufficiency (1%). The most common adverse reactions (≥20%) were musculoskeletal pain (41%), fatigue (40%), rash (30%), diarrhea (27%), pruritus (23%), and hypothyroidism (21%).

In KEYNOTE-868, when KEYTRUDA was administered in combination with chemotherapy (paclitaxel and carboplatin) to patients with advanced or recurrent endometrial carcinoma (n=382), serious adverse reactions occurred in 35% of patients receiving KEYTRUDA in combination with chemotherapy, compared to 19% of patients receiving placebo in combination with chemotherapy (n=377). Fatal adverse reactions occurred in 1.6% of patients receiving KEYTRUDA in combination with chemotherapy, including COVID-19 (0.5%) and cardiac arrest (0.3%). KEYTRUDA was discontinued for an adverse reaction in 14% of patients. Adverse reactions occurring in patients treated with KEYTRUDA and chemotherapy were generally similar to those observed with KEYTRUDA alone or chemotherapy alone, with the exception of rash (33% all Grades; 2.9% Grades 3-4).

Adverse reactions occurring in patients with MSI-H or dMMR endometrial carcinoma who received KEYTRUDA as a single agent were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a single agent.

Adverse reactions occurring in patients with TMB-H cancer were similar to those occurring in patients with other solid tumors who received KEYTRUDA as a single agent.

Adverse reactions occurring in patients with recurrent or metastatic cSCC or locally advanced cSCC were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.

In KEYNOTE-522, when KEYTRUDA was administered with neoadjuvant chemotherapy (carboplatin and paclitaxel followed by doxorubicin or epirubicin and cyclophosphamide) followed by surgery and continued adjuvant treatment with KEYTRUDA as a single agent (n=778) to patients with newly diagnosed, previously untreated, high-risk early-stage TNBC, fatal adverse reactions occurred in 0.9% of patients, including 1 each of adrenal crisis, autoimmune encephalitis, hepatitis, pneumonia, pneumonitis, pulmonary embolism, and sepsis in association with multiple organ dysfunction syndrome and myocardial infarction. Serious adverse reactions occurred in 44% of patients receiving KEYTRUDA; those ≥2% were febrile neutropenia (15%), pyrexia (3.7%), anemia (2.6%), and neutropenia (2.2%). KEYTRUDA was discontinued in 20% of patients due to adverse reactions. The most common reactions (≥1%) resulting in permanent discontinuation were increased ALT (2.7%), increased AST (1.5%), and rash (1%). The most common adverse reactions (≥20%) in patients receiving KEYTRUDA were fatigue (70%), nausea (67%), alopecia (61%), rash (52%), constipation (42%), diarrhea and peripheral neuropathy (41% each), stomatitis (34%), vomiting (31%), headache (30%), arthralgia (29%), pyrexia (28%), cough (26%), abdominal pain (24%), decreased appetite (23%), insomnia (21%), and myalgia (20%).

In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had not been previously treated with chemotherapy in the metastatic setting (n=596), fatal adverse reactions occurred in 2.5% of patients, including cardio-respiratory arrest (0.7%) and septic shock (0.3%). Serious adverse reactions occurred in 30% of patients receiving KEYTRUDA in combination with chemotherapy; the serious reactions in ≥2% were pneumonia (2.9%), anemia (2.2%), and thrombocytopenia (2%). KEYTRUDA was discontinued in 11% of patients due to adverse reactions. The most common reactions resulting in permanent discontinuation (≥1%) were increased ALT (2.2%), increased AST (1.5%), and pneumonitis (1.2%). The most common adverse reactions (≥20%) in patients receiving KEYTRUDA in combination with chemotherapy were fatigue (48%), nausea (44%), alopecia (34%), diarrhea and constipation (28% each), vomiting and rash (26% each), cough (23%), decreased appetite (21%), and headache (20%).

Lactation

Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the last dose.

THINKING THEY NEED LERONLIMAB BIGLY.

NOW THEY GO FROM INTRAVENOUS TO INJECTION.... CLAIMING IMPROVEMENT LEADING TO APPROVAL
https://finance.yahoo.com/news/positive-phase-iii-data-gives-merck-potential-boost-for-blockbuster-keytruda-in-injection-form-150009481.html

ATTN: MERCK HAS CLOUT BUT REAL PROBLEMS WITH THEIR SEMI EFFECTIVE NOT TOO SAFE OF A DRUG. THE COMPETITION IS GOING TO WANT TO JUMP ON LERONLIMAB IF MERCK FAILS TO.... ALL IMO OF COURSE.

$$$$CYDY$$$$ 2025 LOVING IT

Can you clarify? What 2 million shares? What dump?

Maybe Melissa Hodgman at the SEC would support his claim. However, I do believe she as been shitcanned or demoted.
Yes, shorts and flippers take a dump. Longs accumulate.

How so do I love my weekends!!

$$CYDY$$ May 2025, a day to go of infamy.

Who said anything about a PR. Just asking if you like Mondays.

Why are you so mad, bent out of shape over a simple question, nobody’s crying FF, again, if this is a scam, shouldn’t you be on the horn with the FDA to tell them their getting hood winked, give them a call and let us know what they tell you

As usual: you b*shit all along, crying victory when the stock moves up, crying silently when it moves down.

And trying to make stupid bets about PRs. Ah I understand why: because the only business of Cytodyn is to write PRs and to sell shares

That is literally the definition of a pump & dump fraud and you are part of this scam, Black Ops.

How do you feel about Monday’s

Now that 2+ million shares have been dumped on longs, we will know who was the dumper:
- If a SEC filing comes in, it was an investor, or a large shareholder
- If no SEC filing, it was a smaller shareholder - one of the pump crownies, or a mom & pop investor who realized the scam that this pump & dump operation is and got disgusted

That was nice. Same operation as every time before.

Like he said, no one takes you serious, you got your feelings hurt, ok, move on, oh, and we do laugh at you FF

What

Tell us all about your "colleagues". ...Let me guess, you don't understand the question, right?
I don't doubt many people are laughing at the trading here.
Just answer one question, how long are you sticking around this time?...don't understand that question either?

I can’t take you seriously this is comical. My colleagues would laugh at you.

I can’t take you seriously this is comical. My colleagues would laugh at you.

Trying to dumb it down. It is what basher's understand.

LOL, maybe she will get it, maybe!!! Hello

Or the one year chart. You got it. Take it away Johnny Canales.

What an absolutely stupid comparison. Exactly what I'd expect from a pumper.

Leronlimab is gathering lots of attention from new sources and those who wrote about it back prior to 2016 china virus assault on humanity.

NO doubt some tree wizard or johnny come lately will wonder why leronlimab is not a stand alone drug and must be used in conjunction with other drugs in study.
Their all too limited understanding of pharma trials and studies is readily apparent. What are they doing here?

https://clinicalinfo.hiv.gov/en/drugs/leronlimab/patient

A history class is in order when spike protein intake affect the cognitive regions of the brain. They might want to get on some general use leronlimab when available since it crosses the bbb.

Appears leronlimab is pretty powerful all by it's lonesome. Packs a punch and props up other drugs too much less effective standing alone yet somehow approved!!

Has been for a few years now. Listerine to the rescue.

Your commendable editorial ability to synopsize data aforementioned in publications should be understandable by most reader here
and elsewhere that this will surely be forwarded. Even our resident statistician can input this into his computer and come up with a bullish conclusion.
Hopefully many will grasp the challenge and take further action. What a shame it would be to have to chase the share price once this data
is revealed at large. Sometimes Europeans go ape over data especially the Germans ... old Germans before the onslaught that would be.
However, once the "cat is out of the bag" it may well become an onslaught of epic proportions. Slow to happen at first and then all of a sudden
things take off with a bang. This is the nature of change when a new remedy to a problem arises.

Thanks again for investing your time and money to help the general public become aware of a great new proposed addition to medicine.
May many lives be saved.

I like strawberry preserves on my whole wheat peanut butter sandwich. Combo' s work better together. Still waiting to find out if leronlimab is the peanut butter, jam or the bread that holds it together.